Indian Vaccine Maker Bharat Biotech Considers $500 Million IPO
Bharat Biotech International Ltd., a leading Indian vaccine developer, is reportedly considering an initial public offering (IPO). According to people familiar with the matter, the company could look to raise more than $500 million through the listing.
Discussions are currently ongoing. The final details of the deal, including the total size and the timing of the launch, could still change. Bharat Biotech did not immediately respond to a request for comment regarding the private discussions.
About Bharat Biotech
Founded in 1996, Bharat Biotech is a major player in global healthcare. The company states it has delivered more than 9 billion vaccine doses worldwide. Its extensive product list includes vaccines for Covid-19 and Hepatitis B, along with treatments for burns and diarrhea.
Current State of the Indian IPO Market
India’s market for new share sales has had a quiet start to 2026. This follows two record breaking years of fundraising. Several factors have put pressure on the stock market recently, including:
- Slower growth in corporate earnings.
- Uncertainty regarding global trade.
- Inconsistent investment from foreign buyers.
Despite the slow start, several large offerings are expected soon. In addition to Bharat Biotech, major companies in the pipeline include wireless carrier Jio Platforms Ltd., the National Stock Exchange of India Ltd., and various property firms.
Also Read : Sridhar Vembu’s Guide to Careers That Will Survive the Rise of AI
